BURLINGAME, Calif.--(BUSINESS WIRE)--Cala Health, Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, announced that the U.S. Food and Drug Administration (FDA) ...
SAN MATEO, Calif., April 7, 2025 /PRNewswire/ -- Cala, the bioelectronic medicine leader, who recently raised an oversubscribed growth financing round and was recognized on Fast Company's annual top ...
Cala announced the appointment of Deanna Harshbarger as Chief Executive Officer (CEO) and as a member of the Company's Board of Directors, effective immediately. Concurrently, Cala has appointed ...
- Data are a stark reminder that ET-related healthcare system costs are under-appreciated and underscore the potential of Cala Trio to address the needs of patients and payers - BURLINGAME, ...
SAN MATEO, Calif. and HONOLULU, Oct. 6, 2025 /PRNewswire/ -- Cala ®, the bioelectronic medicine leader, announced today the publication of a groundbreaking study in the journal Brain Stimulation ...
A wrist-worn, AI-driven transcutaneous peripheral nerve stimulator is linked to greater improvement in patients with ...
Cala Health, a wearable neuromodulation therapy startup focused on chronic diseases, has closed a $50 million Series C financing round. Novartis, Baird Capital, LifeSci Venture Partners, TriVentures ...
Cala Health has finalised the initial closing of an oversubscribed growth round of $50m to support the expansion of patient access to its neurostimulation therapy. Nexus NeuroTech Ventures and Vertex ...
Editor's note: This article has been updated with a quote from Cala Health's CEO. Calif.-based Cala Health, the maker of wearable neuromodulation therapy, announced that it has completed the initial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback